The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as mono...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Rini, Brian I., Battle, Dena, Figlin, Robert A., George, Daniel J., Hammers, Hans, Hutson, Tom, Jonasch, Eric, Joseph, Richard W., McDermott, David F., Motzer, Robert J., Pal, Sumanta K., Pantuck, Allan J., Quinn, David I., Seery, Virginia, Voss, Martin H., Wood, Christopher G., Wood, Laura S., Atkins, Michael B.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Position Article and Guidelines
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6924043/
https://ncbi.nlm.nih.gov/pubmed/31856918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0813-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars